Dare Bioscience (NASDAQ:DARE) Announces Earnings Results

Dare Bioscience (NASDAQ:DARE) released its earnings results on Thursday. The biotechnology company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.05, FiscalAI reports. The firm had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.01 million.

Dare Bioscience Stock Down 1.6%

Shares of NASDAQ:DARE traded down $0.03 during trading on Friday, hitting $1.86. 67,789 shares of the company were exchanged, compared to its average volume of 489,792. Dare Bioscience has a 1-year low of $1.76 and a 1-year high of $9.19. The company has a market capitalization of $25.07 million, a P/E ratio of -0.87 and a beta of 1.14. The business’s 50 day moving average is $2.06 and its 200-day moving average is $2.41.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on DARE shares. Maxim Group upgraded shares of Dare Bioscience from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research report on Thursday, September 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Dare Bioscience in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Dare Bioscience to a “hold” rating in a report on Saturday, August 16th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $10.00.

About Dare Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.